Cover Image

Establishing a Relationship between In Vitro Potency in Cell-Based Assays and Clinical Efficacious Concentrations for Approved GLP-1 Receptor Agonists

<b>Background:</b> Glucagon-like peptide-1 receptor agonists (GLP-1RAs) play an important role in the treatment of type 2 diabetes (T2D) and obesity. The relationship between efficacy and dosing regimen has been studied extensively for this class of molecules. However, a comprehensive an...

Full description

Saved in:

Bibliographic Details
Main Authors:	Alessandro Boianelli (Author), Pär Nordell (Author), Joseph Earl (Author), Jacqueline Naylor (Author), David Hornigold (Author), Rasmus Jansson Löfmark (Author), Monika Sundqvist (Author)
Format:	Book
Published:	MDPI AG, 2024-10-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

GLP-1 agonists in treatment of obesity
by: Władysław Orłowski, et al.
Published: (2023)

Population pharmacokinetics of the GIP/GLP receptor agonist tirzepatide
by: Karen Schneck, et al.
Published: (2024)

Danuglipron - an innovate GLP agonist - literature short review
by: Agata Frańczuk, et al.
Published: (2024)

INITIATING PATIENTS ON GLP-1/COMBINED GLP-1 AND GIP AGONISTS: A QUALITY IMPROVEMENT PROJECT
by: Shreya Srivastava, MD, MPH
Published: (2024)

GLP-1 receptor agonists and myocardial metabolism in atrial fibrillation
by: Jiani Zhong, et al.
Published: (2024)

Retatrutide - revolutionary recently developed GLP agonist - literature review
by: Patrycja Brzozowska, et al.
Published: (2024)

Glucagon-like peptide-1 (GLP-1) agonists in the treatment of obesity
by: Magdalena Mazurek, et al.
Published: (2023)

The Impact of GLP-1 Agonists on Depression Treatment: A Literature Review
by: Paulina Lemieszek, et al.
Published: (2024)

GLP-1 Receptor Agonists and Coronary Arteries: From Mechanisms to Events
by: Aurélie Pahud de Mortanges, et al.
Published: (2022)

A potentially serious adverse effect of GLP-1 receptor agonists
by: Jinmiao Lu, et al.
Published: (2023)

The Use of GLP-1 Receptor Agonists in the Treatment of Obesity in Women with PCOS
by: Aleksandra Jaroń, et al.
Published: (2024)

Surrogate potency assays: Comparison of binding profiles complements dose response curves for unambiguous assessment of relative potencies
by: Robert Karlsson, et al.
Published: (2018)

Rapid Turbidimetric Assay to Determine the Potency of Daptomycin in Lyophilized Powder
by: Eliane Gandolpho Tótoli, et al.
Published: (2015)

Healthcare professionals' perceptions and management of obesity & knowledge of glucagon, GLP‐1, GIP receptor agonists, and dual agonists
by: W. Timothy Garvey, et al.
Published: (2024)

Designing a Dual GLP-1R/GIPR Agonist from Tirzepatide: Comparing Residues Between Tirzepatide, GLP-1, and GIP
by: Wang L
Published: (2022)

Pharmacovigilance study of GLP-1 receptor agonists for metabolic and nutritional adverse events
by: Long He, et al.
Published: (2024)

GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art
by: Michael A. Nauck, et al.
Published: (2021)

A fully validated microbiological assay to evaluate the potency of ceftriaxone sodium
by: Maria Luisa Manfio, et al.
Published: (2013)

A meta-analysis of the incidence of acne vulgaris in patients treated with GLP-1 agonists
by: Oluwafunke O. Ogunremi, BS, et al.
Published: (2024)

Impact of GLP-1 Receptor Agonists on Psoriasis and Cardiovascular Comorbidities: A Narrative Review
by: Haran K, et al.
Published: (2024)

Timing of GLP-1 Receptor Agonist Initiation for Treatment of Type 2 Diabetes in the UK
by: Kristina S. Boye, et al.
Published: (2019)

GLP-1 Receptor Agonists in Diabetic Kidney Disease: From Clinical Outcomes to Mechanisms
by: Daiji Kawanami, et al.
Published: (2020)

A clinical review of GLP-1 receptor agonists: efficacy and safety in diabetes and beyond
by: Lalita Prasad-Reddy, et al.
Published: (2015)

Development of Syringaldehyde as an Agonist of the GLP-1 Receptor to Alleviate Diabetic Disorders in Animal Models
by: Jenpei Lee, et al.
Published: (2024)

Effect of GLP-1 Receptor Agonist on Ischemia Reperfusion Injury in Rats with Metabolic Syndrome
by: Marko Ravic, et al.
Published: (2024)

GLP-1 receptor agonists in diabetic kidney disease: current evidence and future directions
by: Ji Hee Yu, et al.
Published: (2022)

Obesity medication lorcaserin activates brainstem GLP-1 neurons to reduce food intake and augments GLP-1 receptor agonist induced appetite suppression
by: Stefan Wagner, et al.
Published: (2023)

Development and validation of a rapid turbidimetric assay to determine the potency of norfloxacin in tablets
by: Lucas Chierentin, et al.
Published: (2015)

Call to action: Understanding the differences in the use of SGLT-2 inhibitors and GLP-1 receptor agonists
by: Apurva Khedagi, et al.
Published: (2023)

The development of an oral GLP-1 receptor agonist for the management of type 2 diabetes: evidence to date
by: Antza C, et al.
Published: (2019)

GLP-1 Receptor Agonists: A Promising Therapy for Modern Lifestyle Diseases with Unforeseen Challenges
by: Patrycja Kupnicka, et al.
Published: (2024)

Rational Design by Structural Biology of Industrializable, Long-Acting Antihyperglycemic GLP-1 Receptor Agonists
by: Lei Sun, et al.
Published: (2022)

GLP-1 Receptor Agonists in the Treatment of Patients with Type 2 Diabetes and Chronic Kidney Disease
by: Joshua J. Neumiller, et al.
Published: (2022)

Characterization of a single reporter-gene potency assay for T-cell-dependent bispecific molecules
by: Ho Young Lee, et al.
Published: (2019)

Research progress on substitution of in vivo method(s) by in vitro method(s) for human vaccine potency assays
by: Xuanxuan Zhang, et al.
Published: (2023)

Design of a highly potent GLP-1R and GCGR dual-agonist for recovering hepatic fibrosis
by: Nazi Song, et al.
Published: (2022)

Potential Roles of Glucagon-Like Peptide 1 Receptor Agonists (GLP-1 RAs) in Nondiabetic Populations
by: Dan Xu, et al.
Published: (2022)

Efficacy and Safety of GLP-1 Receptor Agonists for Type 2 Diabetes Mellitus Treatment: Systematic Review
by: Ana Paula Martins, et al.
Published: (2016)

Next generation GLP-1/GIP/glucagon triple agonists normalize body weight in obese mice
by: Patrick J. Knerr, et al.
Published: (2022)

The potencies and neurotoxicity of intrathecal levobupivacaine in a rat spinal model: Effects of concentration
by: Luyue Gao, et al.
Published: (2023)